samedan logo
 
 
 
spacer
home > ebr > summer 2004 > european life sciences
PUBLICATIONS
European Biopharmaceutical Review

European Life Sciences

As the biotech sector continues to mature, its leading companies will deliver more and more products thereby dramatically improving overall sentiment towards the sector. Despite the investor challenges experienced in recent years, over the past 12-18 months we have witnessed a significant and sustained upswing in the US and European markets, as well as in the biotechnology sector in general. On the whole, the prices of quoted companies in both the US and Europe significantly improved over the year to December 2003, with the NASDAQ Biotech Index up more than 50 per cent over the previous 12 months (1). However, since March 2004 there has been a slight correction in both US and European biotech stocks (as shown in Figure 1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Mark Clement, Chief Executive of Merlin Biosciences

Mark Clement is Chief Executive Officer at Merlin Biosciences. He joined Merlin in March 2000 and serves as Chief Executive. In 1997, he founded MCC Services, a corporate finance consultancy, where he led assignments from nine life sciences companies, including four Fund I investments. In 1992, he co-founded Celsis International plc (a specialist in microbial risk management), where he served as Group Finance Director with responsibility for both finance and European operations. Prior to this, he spent a year at WestLB Panmure as an Associate Director (Corporate Finance). Mark is a Fellow of the Institutes of Chartered Accountants in England and Wales, the Securities Institute and the Insolvency Practitioners Association.

spacer
Mark Clement
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera reinforces its value proposition with a refreshing visual identity

At Nemera, we have been successfully providing high quality drug delivery device solutions to our customers and patients for years. We design and manufacture devices with the ultimate goal to improve patient outcomes and experience.
More info >>

White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement